A Phase 1 Dose-Finding and Dose Optimization-Expansion Study of KIVU-305 in Participants With Locally Advanced or Metastatic Solid Tumors
Latest Information Update: 01 May 2026
At a glance
- Drugs KIVU 305 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Kivu Bioscience
Most Recent Events
- 22 Apr 2026 Status changed from planning to not yet recruiting.
- 06 Mar 2026 New trial record